All News

Negative interactions with doctors' offices can have serious consequences, so play nice.

We explore what happened and talk to CVS corporate to get their take.

Officials with the FDA have approved angiotensin II (Giapreza, La Jolla Pharmaceutical Company) injection for intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock.

The results of all trials showed that the use of LABA with ICS does not significantly increase the risk of serious asthma outcomes compared to ICS alone.

A combination of long-acting beta agonists and inhaled corticosteroids may not increase mortality risk for patients with asthma.

Treatment with hydroxyurea increased hemoglobin F levels for patients with sickle cell anemia.

The FDA issued new draft guidances to expedite the approval of novel targeted drugs.

Nivolumab (Opdivo) showed better tolerability than ipilimumab (Yervoy) in patients with metastatic melanoma.

Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.

The cornerstone of working with patients is sharing decision-making and presenting information in a way that helps patients understand the risks and benefits of various choices.

Health care providers can administer egg-based influenza vaccines to people with egg allergy without taking precautions, according to a newly-updated influenza vaccine practice parameter from the Influenza Vaccine and Egg Allergy Practice Parameter Workgroup commissioned by Joint Task Force on Practice Parameters (JTFPP).

Unmarried patients were 45% more likely to die from heart disease than married patients.

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Priority areas that pharmacists should focus on ahead of USP .

Cariprazine is an oral atypical antipsychotic currently approved for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder.

Danielle McDonald, PharmD, talks about her residency at Rutgers, the State University of New Jersey.

Rattlesnake pills have received media attention due to their link with Salmonella infection.

HMG-CoA reductase inhibitors are a class of lipid-lowering medications. Here is a look at guidelines and studies for health care professionals.

Officials with the FDA have approved ertugliflozin (Steglatro, Merck and Pfizer) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Cabozantinib (Cabometyx) was previously granted priority review as a therapy for advanced renal cell carcinoma.

Bosutinib (Bosulif) was approved by the FDA to treat patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia.

Trastuzumab (Herceptin) is indicated to treat HER2+ breast and gastric cancers.

Patients treated with chemotherapy biweekly were 17% less likely to experience breast cancer recurrence over 10 years.

Human Vaccines Project seeks to decode the human immune system to facilitate accelerated development of diagnostics, vaccines and therapies for major global diseases.

Some health care antiseptics currently on the market won’t be affected by FDA decision.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Officials with the FDA have finalized a rule that bans 24 active ingredients, including triclosan, from being marketed and sold in OTC health care antiseptic products.